Laura Machín Galarza

Prof. Laura Machín Galarza

Institute of Pharmacy and Foods Sciences, University of Havana, Havana, La Habana, Cuba
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in ACS Omega
Verified
Journal Article
Closed access
BSBahare Salehi
Bahare Salehi
Laura Machín GalarzaLaura Machín Galarza
Laura Machín Galarza
LMLianet Monzote
Lianet Monzote
Javad Sharifi-RadJavad Sharifi-Rad
Javad Sharifi-Rad
SEShahira M. Ezzat
Shahira M. Ezzat
William C. ChoWilliam C. Cho
William C. Cho

20 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Laura Machín GalarzaLaura Machín Galarza
Laura Machín Galarza
BTBeatriz Tamargo
Beatriz Tamargo
APAbel Piñón
Abel Piñón
RARegla C. Atíes
Regla C. Atíes
RSRamón Scull
Ramón Scull
LMLianet Monzote
Lianet Monzote
Leishmaniasis is a group of neglected tropical diseases caused by protozoan parasites of the Leishmania genus. The absence of effective vaccines and the limitations of current treatments make the search for effective therapies a real need. Different plant-derived essential oils (EOs) have shown antileishmanial effects, in particular from Bixa orellana L. (EO-Bo) and Dysphania ambrosioides (L.) Mosyakin & Clemants (EO-Da). In the present study, the EO-Bo and EO-Da, formulated in nanocochleates (EO-Bo-NC and EO-Da-NC, respectively), were evaluated in vitro and in vivo against L. amazonensis. The EO-Bo-NC and EO-Da-NC did not increase the in vitro inhibitory activity of the EOs, although the EO-Bo-NC showed reduced cytotoxic effects. In the animal model, both formulations (30 mg/kg/intralesional route/every 4 days/4 times) showed no deaths or weight loss greater than 10%. In the animal (mouse) model, EO-Bo-NC contributed to the control of infection (p < 0.05) in comparison with EO-Bo treatment, while the mice treated with EO-Da-NC exhibited larger lesions (p < 0.05) compared to those treated with EO-Da. The enhanced in vivo activity observed for EO-Bo-NC suggests that lipid-based nanoformulations like nanocochleates should be explored for their potential in the proper delivery of drugs, and in particular, the delivery of hydrophobic materials for effective cutaneous leishmaniasis treatment.

1 February 2021 in Parasitology International
Verified
Journal Article
Closed access
Laura Machín GalarzaLaura Machín Galarza
Laura Machín Galarza
RNRachel Nápoles
Rachel Nápoles
LGLars Gille
Lars Gille
LMLianet Monzote
Lianet Monzote

29 November 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GGGerald Geroldinger
Gerald Geroldinger
MTMatthias Tonner
Matthias Tonner
JQJudith Quirgst
Judith Quirgst
MWMartin Walter
Martin Walter
SSSritama De Sarkar
Sritama De Sarkar
LGLars Gille
Lars Gille

9 June 2017 in Medicines
Verified
Journal Article
Open access
PDF file
BTBeatriz Tamargo
Beatriz Tamargo
LMLianet Monzote
Lianet Monzote
APAbel Piñón
Abel Piñón
Laura Machín GalarzaLaura Machín Galarza
Laura Machín Galarza
MGMarley García
Marley García
William N. SetzerWilliam N. Setzer
William N. Setzer
Background: Leishmaniasis is a zoonotic disease caused by protozoan parasites from Leishmania genus. Currently, there are no effective vaccines available and the available therapies are far from ideal. In particular, the development of new therapeutic strategies to reduce the infection caused by Leishmania amazonensis could be considered desirable. Different plant-derived products have demonstrated antileishmanial activity, including the essential oil (EO) from Artemisia absinthium L. (EO-Aa), Asteraceae. Methods: In the present study, the EO-Aa formulated in nanocochleates (EO-Aa-NC) was investigated in vitro against intracellular amastigotes of L. amazonensis and non-infected macrophages from BALB/c mice. In addition, the EO-Aa-NC was also evaluated in vivo against on experimental cutaneous leishmaniasis, which body weight, lesion progression, and parasite load were determined. Results: EO-Aa-NC displayed IC50 values of 21.5 ± 2.5 μg/mL and 27.7 ± 5.6 μg/mL against intracellular amastigotes of L. amazonensis and non-infected peritoneal macrophage, respectively. In the animal model, the EO-Aa-NC (30 mg/kg/intralesional route/every 4 days 4 times) showed no deaths or weight loss greater than 10%. In parallel, the EO-Aa-NC suppressed the infection in the murine model by approximately 50%, which was statistically superior (p < 0.05) than controls and mice treated with EO-Aa. In comparison with Glucantime®, EO-Aa-NC inhibited the progression of infection as efficiently (p > 0.05) as administration of the reference drug. Conclusions: Encochleation of EO-Aa resulted in a stable, tolerable, and efficacious antileishmanial formulation, facilitating systemic delivery of EO, with increased activity compared to administration of the free EO-Aa. This new formulation shows promising potential to future studies aimed at a new therapeutic strategy to treat leishmaniasis.

29 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LMLianet Monzote
Lianet Monzote
Laura Machín GalarzaLaura Machín Galarza
Laura Machín Galarza
AGAdiel González
Adiel González
RSRamón Scull
Ramón Scull
YGYamilet I. Gutiérrez
Yamilet I. Gutiérrez
William N. SetzerWilliam N. Setzer
William N. Setzer
Pimenta dioica L. is one the most recognized species with diverse biological activities. In this study, in vitro activity and in vivo efficacy of essential oil from P. dioica (EO-Pd) was evaluated. The main compound was also included in the animal studies and its in silico prediction related to biological activities, molecular ligands, drug likeness, and ADME (absorption, distribution, metabolism, and excretion) properties are listed. The chemical composition analyzed by GC-MS retrieved 45 components, which the most abundant compound was the eugenol (80.1%). The EO-Pd was able to inhibit the growth of L. amazonensis (IC50 = 9.7 ± 0.7 and 11.3 ± 2.1 µg/mL, promastigotes and amastigotes, respectively). The cytotoxicity assay showed a CC50 of 104.5 ± 0.9 µg/mL and a selectivity index of 9. In the model of cutaneous leishmaniasis in BALB/c mice, the effect of EO-Pd and eugenol was observed after treatment at 30 mg/kg by intralesional route with 5 administrations every 4 days. In the in silico predictions, some targets that justified the antileishmanial activity of eugenol and good drug like properties for this compound, were obtained. This study showed for first time the potential of EO-Pd to inhibit L. amazonensis, which could be linked to the activity of major compound eugenol.